Ranolazine (dihydrochloride)

95635-56-6

C24H35Cl2N3O4

DMSO : >= 50 mg/mL (99.91 mM); H2O : >= 50 mg/mL (99.91 mM)

Membrane Transporter/Ion Channel; Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling

Ranolazine dihydrochloride (CVT 303 dihydrochloride; RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value: Target: sodium-dependent calcium channel Ranolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.